BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Authors » John Fox

Articles by John Fox

Antifungal drug could prove to be answer to multidrug resistance

Jan. 20, 2016
By John Fox
HONG KONG — Chinese researchers have discovered that an antifungal drug can efficiently block bacterial virulence due to Staphylococcus aureus infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) strains of the bacterium, in mouse models of infection, they reported in the Jan. 18, 2015, edition of Nature Chemical Biology.
Read More

H1N1 swine flu shows the potential to transmit in humans

Jan. 6, 2016
By John Fox
HONG KONG — Chinese virologists have discovered that following a lengthy evolutionary period in pigs, Eurasian H1N1 avian-like (EAH1N1) swine influenza viruses (SIVs) have acquired the ability to transmit effectively in humans, suggesting that urgent action may be necessary in order to prevent a new readily transmissible swine flu epidemic.
Read More

Addressing resistance Artemisinin’s targets may yield new antimalarials

Jan. 5, 2016
By John Fox

HONG KONG — A study by scientists at the National University of Singapore (NUS) has identified more than 100 proteins that are actively targeted by artemisinin in the malarial parasite Plasmodium falciparum, which explains why artemisinin is such an effective antimalarial drug and could facilitate the development of urgently needed effective malaria treatment strategies.


Read More

H1N1 swine flu shows the potential to transmit in humans

Jan. 5, 2016
By John Fox
HONG KONG – Chinese virologists have discovered that following a lengthy evolutionary period in pigs, Eurasian H1N1 avian-like (EAH1N1) swine influenza viruses (SIVs) have acquired the ability to transmit effectively in humans, suggesting that urgent action may be necessary in order to prevent a new readily transmissible swine flu epidemic.
Read More

Artemisinin's targets may yield new antimalarials

Dec. 31, 2015
By John Fox
HONG KONG — A study by scientists at the National University of Singapore (NUS) has identified more than 100 proteins that are actively targeted by artemisinin in the malarial parasite Plasmodium falciparum, which explains why artemisinin is such an effective antimalarial drug and could facilitate the development of urgently needed effective malaria treatment strategies.
Read More

Brain balance mechanism key to neurology treatments

Dec. 23, 2015
By John Fox
HONG KONG – Japanese and French researchers have discovered the cellular signaling mechanism whereby the balance of disturbed inhibitory synaptic connections is restored, which could have important implications for the management of neurological disorders such as epilepsy and possibly even autism, they reported in the Dec. 17, 2015, issue of Cell Reports.
Read More

Brain balance mechanism key to neurology treatments

Dec. 22, 2015
By John Fox
HONG KONG – Japanese and French researchers have discovered the cellular signaling mechanism whereby the balance of disturbed inhibitory synaptic connections is restored, which could have important implications for the management of neurological disorders such as epilepsy and possibly even autism, they reported in the Dec. 17, 2015, issue of Cell Reports.
Read More

Small molecule clears amyloid beta deposits in mouse brains

Dec. 16, 2015
By John Fox
HONG KONG — A small molecule has been shown to be capable of breaking down amyloid beta deposits in a study of the brains of mice exhibiting the symptoms of Alzheimer's disease (AD), an important finding that may lead to the development of new treatments for the different stages of AD, according to the results of a study by Korean researchers.
Read More

Small molecule clears amyloid beta deposits in mouse brains

Dec. 11, 2015
By John Fox
HONG KONG – A small molecule has been shown to be capable of breaking down amyloid beta deposits in a study of the brains of mice exhibiting the symptoms of Alzheimer's disease (AD), an important finding that may lead to the development of new treatments for the different stages of AD, according to the results of a study by Korean researchers.
Read More

Synapse discovery could lead to new Alzheimer's treatments

Dec. 9, 2015
By John Fox
HONG KONG – Australian researchers led by the University of New South Wales (UNSW) have discovered the mechanism whereby synaptic connections between brain cells are destroyed in the early stages of Alzheimer's disease (AD), a key finding that clears the way for new research on urgently needed treatments for the currently incurable degenerative brain disease.
Read More
Previous 1 2 … 49 50 51 52 53 54 55 56 57 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing